4 results
With a simple set of clinical tests we want to measure speech recognition performance in a group of normal hearing (NH) individuals and in a group of individuals with a specific hearing impairment. The purpose is to determine if and to what extent…
Primary: To evaluate the efficacy of FF/UMEC/VI to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD. Secondary: Long term safety and other efficacy parameters.
Primary:To evaluate the effects of FF/UMEC/VI on lung function compared with FF/VI after 24 weeks of treatmentSecondary:To assess the efficacy (exacerbations), FEV1 3h post dose, asthma symptoms, safety and tolerability.
To show the protective value and to measure cost effectiveness of higher Ig dosing on progression of lung disease in PAD.